ClinicalTrials.gg
CompletedNCT01609556IMGN853-0401Updated Feb 17, 2021Results posted

First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors

A Phase 1 interventional study of Mirvetuximab soravtansine in Tumors, sponsored by ImmunoGen, Inc.. Completed at 12 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-17.

Sponsored by ImmunoGen, Inc. (part of AbbVie) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
206
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to test mirvetuximab soravtansine (IMGN853) in participants with ovarian cancer and other FOLR-1 positive tumors.

Read the detailed description

The study consists of a dose-escalation phase that will evaluate 2 dosing schedules (Schedule A and Schedule B) of mirvetuximab soravtansine and up to 5 dose-expansion groups at the maximum tolerated dose (MTD). The first 4 escalation cohorts will be single participant cohorts. Subsequent escalation cohorts will use a standard 3+3 design, with each cohort consisting of 3 or 4 to 6 participants. Data were collected and analysed for the escalation and expansion groups by dose schedule and not by individual dose.

02

Conditions studied

  • Tumors

Browse trials for

Keywords

  • FOLR-1 solid tumors
03

In context

Neoplasms

10,832 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.

This study's enrollment of 206 is above the median of 60 across 7,712 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

ImmunoGen, Inc. is the lead sponsor of 16 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.

First submitted before ImmunoGen, Inc. became part of AbbVie.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with advanced solid tumor that is to standard treatment, for which no standard treatment is available, or the participant refuses standard therapy.
  • Participants must be willing to provide an block or slides for biomarker analysis.
  • (ECOG) Performance Status 0 or 1.
  • Time from prior therapy:

    1. Systemic anti-neoplastic therapy: five half-lives or four weeks, whichever is shorter (6 weeks for prior nitrosoureas or mitomycin C).
    2. Radiotherapy: wide-field radiotherapy (for example, greater than [>] 30 percent [%] of marrow-bearing bones) completed at least four weeks, or focal radiation completed at least two weeks, prior to starting study drug.
  • Participants must have recovered or stabilized from all therapy-related toxicities.
  • Major surgery (not including placement of vascular access device or tumor biopsies) must be completed four weeks prior to Day 1. Participants must have recovered or stabilized from the side effects prior to study treatment.
  • Participants must have adequate hematologic, liver and kidney function.
  • Participants with central nervous system (CNS) disease involvement are eligible if they have had resected or have received radiation therapy ending at least 4 weeks prior to study day 1 and they meet all of the following criteria: Residual neurological symptoms less than or equal to (\<=) Grade 1; No dexamethasone requirement; and Follow-up magnetic resonance imaging (MRI) shows no progression of treated lesions and no new lesions appearing.
  • Participants must be willing and able to sign the form, and to adhere to the study visit schedule and other protocol requirements.
  • Women of and men must agree to use effective methods while on study and for at least twelve weeks after the last dose of study drug.
  • Women of childbearing potential must have a negative pregnancy test prior to the first dose of study treatment.

Exclusion criteria

Exclusion Criteria

  • Grade >1 neuropathy.
  • Any active or chronic corneal disorder, including, but not limited to the following: Sjogren's syndrome, Fuch's corneal dystrophy (requiring treatment), history of corneal transplantation, active herpetic keratitis, and also active ocular conditions requiring ongoing treatment/monitoring such as wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, presence of papilledema, acquired monocular vision.
  • Serious concurrent illness, including, but not limited to the following:

    1. active infection including known active or C, (HIV) infection, varicella-zoster virus (shingles) or cytomegalovirus infection or any other known concurrent infectious disease, requiring IV antibiotics within 2 weeks of study enrollment.
    2. Significant cardiac disease such as recent myocardial infarction (\<=6 months prior to Day 1), unstable angina pectoris, uncontrolled congestive heart failure ( >class II), uncontrolled hypertension (greater than or equal to [>=] Version 4.03 [CTCAE v4.03] Grade 3), uncontrolled cardiac arrhythmias, severe aortic stenosis, or >=Grade 3 cardiac toxicity following prior chemotherapy.
    3. History of multiple sclerosis or other demyelinating disease, Eaton-Lambert syndrome (para-neoplastic syndrome), history of hemorrhagic or ischemic stroke within the last six months, or alcoholic liver disease.
    4. Previous clinical diagnosis of treatment-related pneumonitis.
  • Any other concomitant anti-cancer treatment such as immunotherapy, biotherapy, radiotherapy, chemotherapy, investigative therapy, or high-dose ; however, low dose steroids and Luteinizing Hormone Releasing Hormone (LHRH) at doses that have been stable for >=14 days are permitted for participants with prostate cancer.
  • Known to previous monoclonal antibody therapy or maytansinoids.
  • Prior history of solid tumor within the last 3 years except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, in situ breast cancer, in situ prostate cancer (participants must have shown no evidence of active disease for 2 years prior to enrollment).
  • Concomitant administration of folate-containing vitamins.
  • Participants who have received prior or autologous bone marrow transplants.
  • Women of who are pregnant or breast feeding.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
206 participants (actual)

Study arms

  • Experimental
    Dose Escalation: Schedule A (Mirvetuximab Soravtansine Q3W)

    Participants will receive mirvetuximab soravtansine intravenous (IV) infusion on Day 1 of every 21-day (every 3 weeks \[Q3W\]) cycle. Dose escalation for this group schedule will start at 0.15 milligrams per kilogram (mg/kg) and proceed through 7.0 mg/kg. Doses calculated initially based on participant's total body weight (TBW); then from protocol amendment 5 onwards, calculated based on adjusted ideal body weight (AIBW). Participants will continue to receive mirvetuximab soravtansine (for clinical benefit) until unacceptable toxicity or withdrawal of consent, whichever comes first, or until the sponsor terminate the study.

    Drug: Mirvetuximab soravtansine

  • Experimental
    Dose Escalation: Schedule B (Mirvetuximab Soravtansine Weekly)

    Participants will receive mirvetuximab soravtansine IV infusion on Days 1, 8, and 15 of every 28-day cycle. Dose escalation for this group schedule will start at 1.1 mg/kg (calculated based on AIBW) and proceed through 2.5 mg/kg. Participants will continue to receive mirvetuximab soravtansine (for clinical benefit) until unacceptable toxicity or withdrawal of consent, whichever comes first, or until the sponsor terminate the study.

    Drug: Mirvetuximab soravtansine

  • Experimental
    Dose Expansion:EOC Participants(Mirvetuximab Soravtansine Q3W)

    Participants with epithelial ovarian cancer (EOC) will receive mirvetuximab soravtansine 6.0 mg/kg (maximum tolerated dose \[MTD\]) IV infusion on Day 1 of every 21-day (Q3W) cycle (calculated based on AIBW). Participants will continue to receive mirvetuximab soravtansine (for clinical benefit) until unacceptable toxicity or withdrawal of consent, whichever comes first, or until the sponsor terminated the study.

    Drug: Mirvetuximab soravtansine

  • Experimental
    Dose Expansion: EC Participants(Mirvetuximab Soravtansine Q3W)

    Participants with endometrial cancer (EC) will receive mirvetuximab soravtansine 6.0 mg/kg (MTD) IV infusion on Day 1 of every 21-day (Q3W) cycle (calculated based on AIBW). Participants will continue to receive mirvetuximab soravtansine (for clinical benefit) until unacceptable toxicity or withdrawal of consent, whichever comes first, or until the sponsor terminate the study.

    Drug: Mirvetuximab soravtansine

Interventions

  • Mirvetuximab soravtansine IV infusion will be administered as per dose and schedule specified in the respective arms.

    Also known as: IMGN853

06

What researchers measure

Primary outcomes

  1. Dose-Escalation Phase: Maximum Tolerated Dose (MTD) of Mirvetuximab Soravtansine

    MTD was defined as the highest dose at which 1 or fewer among 6 participants or less than or equal to (\<=) 33 percent (%) experienced a dose-limiting toxicity (DLT) (calculated based on adjusted ideal body weight \[AIBW\]). AIBW was calculated as ideal body weight (IBW) + 0.4 \* (actual weight - IBW), where IBW for men was 0.9 \* height in centimeters (cm) - 88 and IBW for women was 0.9 \* height in cm - 92. DLT was defined as a treatment-emergent adverse event (TEAE) or abnormal laboratory value related to study treatment (that is, assessed as unrelated to disease, intercurrent illness, or concomitant medications), including those TEAEs and abnormal laboratory values that resulted in a failure to meet the criteria for re-treatment.

    Time frame: Cycle 1 (21 days)

  2. Dose-Escalation Phase: Recommended Phase 2 Dose (RP2D) of Mirvetuximab Soravtansine

    RP2D was determined by MTD. MTD was defined as the highest dose at which 1 or fewer among 6 participants or \<=33% experienced a DLT. DLT was defined as a TEAE or abnormal laboratory value related to study treatment (that is, assessed as unrelated to disease, intercurrent illness, or concomitant medications), including those TEAEs and abnormal laboratory values that resulted in a failure to meet the criteria for re-treatment. Available clinical data indicated that the MTD defined for the Q3W schedule was equal to the RP2D.

    Time frame: Cycle 1 (21 days)

Secondary outcomes

  1. Number of Participants With TEAEs

    An adverse event (AE) was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to study drug. Severity was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03 on following scale: Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening, Grade 5=death. Serious AEs include death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized the participant and required medical intervention to prevent 1 of the outcomes listed in this definition. TEAEs were defined as any AE that emerged on or after the first dose, and within 28 days of the last dose.

    Time frame: From first dose of study drug up to 28 days after last dose of study drug (maximum exposure: 36 weeks for dose-escalation Schedule A, 101.3 weeks for dose-escalation Schedule B, 124 weeks for dose-expansion EOC, 33.3 weeks for dose-expansion EC)

  2. Number of Participants With Shift From Baseline Grade <=2 in Clinical Laboratory Parameters to Grade 3 or Grade 4 on Study

    Laboratory parameters included serum chemistry (alanine aminotransferase \[ALT\]/serum glutamic pyruvic transaminase \[SGPT\], aspartate aminotransferase \[AST\]/serum glutamic oxaloacetic transaminase \[SGOT\], albumin, alkaline phosphatase, bilirubin, calcium, creatinine, glucose, magnesium, phosphorous, potassium, sodium), hematology (hemoglobin, lymphocytes, neutrophils, platelets, white blood cells) and coagulation (international normalized ratio \[INR\], partial thromboplastin time \[PTT\]). Clinically significant laboratory values were defined as per NCI CTCAE v.03 Grade 3 or higher. A grading (severity) scale was provided with grades ranging from 0 (none), 1 (mild), 2 (moderate), 3 (severe), 4 (life-threatening or disabling), to 5 (death). Only participants who shifted from a baseline value of Grade \<=2 to a post-baseline Grade 3/4 on-treatment, are reported.

    Time frame: From first dose of study drug up to 28 days after last dose of study drug (maximum exposure: 36 weeks for dose-escalation Schedule A, 101.3 weeks for dose-escalation Schedule B, 124 weeks for dose-expansion EOC, 33.3 weeks for dose-expansion EC)

  3. Number of Participants With Clinically Significant Abnormalities in Physical Examination Findings and Vital Signs

    Physical examination included assessments of general appearance, skin, head (eyes, ears, nose, and throat), neck, lungs, heart, abdomen, back, lymph nodes, extremities, and neurological system. Vital signs included assessment of blood pressure, pulse rate, respiratory rate and body temperature.

    Time frame: From first dose of study drug up to 28 days after last dose of study drug (maximum exposure: 36 weeks for dose-escalation Schedule A, 101.3 weeks for dose-escalation Schedule B, 124 weeks for dose-expansion EOC, 33.3 weeks for dose-expansion EC)

  4. Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG)

    Standard ECGs were performed in triplicate at 2- to 5-minute intervals during the study. A single ECG was performed at the end of treatment visit and as clinically indicated.

    Time frame: Baseline up to end of treatment (EOT) (up to maximum 124 weeks)

  5. Number of Participants With Treatment-Emergent Ocular AEs

    Ocular AEs included keratopathy and blurred vision. An AE was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to study drug. TEAEs were defined as any AE that emerged on or after the first dose, and within 28 days of the last dose.

    Time frame: From first dose of study drug up to 28 days after last dose of study drug (maximum exposure: 36 weeks for dose-escalation Schedule A, 101.3 weeks for dose-escalation Schedule B, 124 weeks for dose-expansion EOC, 33.3 weeks for dose-expansion EC)

  6. Maximum Observed Plasma Concentration (Cmax) of Mirvetuximab Soravtansine and Total M9346A Antibody at RP2D

    Pharmacokinetic (PK) parameters were calculated using standard non-compartmental methods. PK analysis of mirvetuximab soravtansine and total M9346A antibody is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.

    Time frame: Cycle 1, 3: Day 1 (pre-infusion; within 10 minutes [min] of EOI; 2, 4, 6, 8 hrs post-infusion); Day 2, 3 (24, 48 hrs post-infusion); Day 4 or 5, 8, 15 (24 hrs post-infusion)

  7. Cmax of Free DM4 and S-Methyl DM4 at RP2D

    PK parameters were calculated using standard non-compartmental methods. PK analysis of free N2'-\[4-\[(3-carboxypropyl)dithio\]-4-methyl-1-oxo-2-sulfopentyl\]-N2'-deacetylmaytansine (DM4) and S-methyl DM4 is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.

    Time frame: Cycle 1, 3: Day 1 (pre-infusion; within 10 min of EOI; 2, 4, 6, 8 hrs post-infusion); Day 2, 3 (24, 48 hrs post-infusion); Day 4 or 5, 8, 15 (24 hrs post-infusion)

  8. Area Under the Plasma Concentration-Time Curve Extrapolated to Infinity (AUC0-inf) of Mirvetuximab Soravtansine and Total M9346A Antibody at RP2D

    PK parameters were calculated using standard non-compartmental methods. PK analysis of mirvetuximab soravtansine and total M9346A antibody is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.

    Time frame: Cycle 1, 3: Day 1 (pre-infusion; within 10 min of EOI; 2, 4, 6, 8 hrs post-infusion); Day 2, 3 (24, 48 hrs post-infusion); Day 4 or 5, 8, 15 (24 hrs post-infusion)

  9. AUC0-inf of Free DM4 and S-Methyl DM4 at RP2D

    PK parameters were calculated using standard non-compartmental methods. PK analysis of free DM4 and S-methyl DM4 is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.

    Time frame: Cycle 1, 3: Day 1 (pre-infusion; within 10 min of EOI; 2, 4, 6, 8 hrs post-infusion); Day 2, 3 (24, 48 hrs post-infusion); Day 4 or 5, 8, 15 (24 hrs post-infusion)

  10. Area Under the Plasma Concentration-Versus Time Curve From Time of Dose Until Tlast (AUClast) of Mirvetuximab Soravtansine and Total M9346A Antibody at RP2D

    PK parameters were calculated using standard non-compartmental methods. PK analysis of mirvetuximab soravtansine and total M9346A antibody is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.

    Time frame: Cycle 1, 3: Day 1 (pre-infusion; within 10 min of EOI; 2, 4, 6, 8 hrs post-infusion); Day 2, 3 (24, 48 hrs post-infusion); Day 4 or 5, 8, 15 (24 hrs post-infusion)

  11. AUClast of Free DM4 and S-Methyl DM4 at RP2D

    PK parameters were calculated using standard non-compartmental methods. PK analysis of free DM4 and S-methyl DM4 is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.

    Time frame: Cycle 1, 3: Day 1 (pre-infusion; within 10 min of EOI; 2, 4, 6, 8 hrs post-infusion); Day 2, 3 (24, 48 hrs post-infusion); Day 4 or 5, 8, 15 (24 hrs post-infusion)

  12. Terminal Half-Life (t1/2) of Mirvetuximab Soravtansine,Total M9346A Antibody, DM4, and S-Methyl DM4 at RP2D

    PK parameters were calculated using standard non-compartmental methods. PK analysis of mirvetuximab soravtansine, total M9346A antibody, DM4, and S-methyl DM4 is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.

    Time frame: Cycle 1, 3: Day 1 (pre-infusion; within 10 min of EOI; 2, 4, 6, 8 hrs post-infusion); Day 2, 3 (24, 48 hrs post-infusion); Day 4 or 5, 8, 15 (24 hrs post-infusion)

  13. Clearance (CL) of Mirvetuximab Soravtansine and Total M9346A Antibody at RP2D

    PK parameters were calculated using standard non-compartmental methods. PK analysis of mirvetuximab soravtansine and total M9346A antibody is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.

    Time frame: Cycle 1, 3: Day 1 (pre-infusion; within 10 min of EOI; 2, 4, 6, 8 hrs post-infusion); Day 2, 3 (24, 48 hrs post-infusion); Day 4 or 5, 8, 15 (24 hrs post-infusion)

  14. CL of DM4 and S-Methyl DM4 at RP2D

    PK parameters were calculated using standard non-compartmental methods. PK analysis of DM4 and S-methyl DM4 is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.

    Time frame: Cycle 1, 3: Day 1 (pre-infusion; within 10 min of EOI; 2, 4, 6, 8 hrs post-infusion); Day 2, 3 (24, 48 hrs post-infusion); Day 4 or 5, 8, 15 (24 hrs post-infusion)

  15. Time to Reach Maximum Observed Concentration (Tmax) of Mirvetuximab Soravtansine, Free DM4, S-Methyl DM4, and Total M9346A Antibody at RP2D

    PK parameters were calculated using standard non-compartmental methods. PK analysis of mirvetuximab soravtansine, free DM4, S-methyl DM4, and total M9346A antibody is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.

    Time frame: Cycle 1, 3: Day 1 (pre-infusion; within 10 min of EOI; 2, 4, 6, 8 hrs post-infusion); Day 2, 3 (24, 48 hrs post-infusion); Day 4 or 5, 8, 15 (24 hrs post-infusion)

  16. Volume of Distribution at Steady State (Vss) of Mirvetuximab Soravtansine Free DM4, S-Methyl DM4, and Total M9346A Antibody at RP2D

    PK parameters were calculated using standard non-compartmental methods. PK analysis of mirvetuximab soravtansine, free DM4, S-methyl DM4, and total M9346A antibody is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.

    Time frame: Cycle 1, 3: Day 1 (pre-infusion; within 10 min of EOI; 2, 4, 6, 8 hrs post-infusion); Day 2, 3 (24, 48 hrs post-infusion); Day 4 or 5, 8, 15 (24 hrs post-infusion)

  17. Objective Response Rate (ORR): Percentage of Participants With Objective Response as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)

    ORR was defined as percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR). CR: Disappearance of all target or non-target lesions. All pathological or non-pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeters (mm). PR: At least 30 percent (%) decrease in the sum of the longest diameters (SoD) of target lesions, taking as reference the baseline SoD.

    Time frame: From first dose of study drug until first BOR of CR or PR (maximum exposure: 36 weeks for dose-escalation Schedule A, 101.3 weeks for dose-escalation Schedule B, 124 weeks for dose-expansion EOC, 33.3 weeks for dose-expansion EC)

  18. Duration of Response (DOR) as Assessed by RECIST v1.1

    DOR was defined as the time from the date of the first response (CR or PR), whichever was recorded first, until the date of progressive disease (PD). PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase. DOR was only defined for participants who had a BOR of CR or PR using the method of Kaplan-Meier.

    Time frame: From the date of first response (CR or PR) until the date of PD (maximum exposure: 36 weeks for dose-escalation Schedule A, 101.3 weeks for dose-escalation Schedule B, 124 weeks for dose-expansion EOC, 33.3 weeks for dose-expansion EC)

  19. Progression-Free Survival (PFS) as Assessed by RECIST v1.1

    PFS was defined as the time from initiation of study drug until PD or death whichever occurred first, estimated using the Kaplan-Meier method. PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions and appearance of new lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.

    Time frame: From first dose of study drug until PD or death whichever occurred first (maximum exposure: 36 weeks for dose-escalation Schedule A, 101.3 weeks for dose-escalation Schedule B, 124 weeks for dose-expansion EOC, 33.3 weeks for dose-expansion EC)

  20. Time to Progression (TTP) as Assessed by RECIST v1.1

    TTP was defined as the time from initiation of study drug until PD, estimated using the method of Kaplan-Meier. PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions and appearance of new lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.

    Time frame: From first dose of study drug until PD (maximum exposure: 36 weeks for dose-escalation Schedule A, 101.3 weeks for dose-escalation Schedule B, 124 weeks for dose-expansion EOC, 33.3 weeks for dose-expansion EC)

  21. Number of Participants With Anti-Drug Antibodies (ADA)

    During the conduct of the study, a single immunogenicity assay was developed to concurrently detect human antibodies against all components of mirvetuximab soravtansine, including the humanized anti-FOLR1 antibody, the cleavable disulfide linker, and the cytotoxic maytansinoid, DM4. Therefore, immunogenicity results were reported as ADA titers, and did not distinguish between human anti-drug or anti-human titers.

    Time frame: Baseline up to follow-up visit (maximum exposure: 36 weeks for dose-escalation Schedule A, 101.3 weeks for dose-escalation Schedule B, 124 weeks for dose-expansion EOC, 33.3 weeks for dose-expansion EC)

  22. Number of Participants With Gynecologic Cancer Intergroup (GCIG) CA-125 Criteria Clinical Responses

    CA-125 response was defined as at least 50% reduction in CA-125 levels from baseline. The date of response corresponded to the date when the CA 125 level was first reduced by 50%.

    Time frame: From first dose of study drug until CA-125 response (maximum exposure: 36 weeks for dose-escalation Schedule A, 101.3 weeks for dose-escalation Schedule B, 124 weeks for dose-expansion EOC, 33.3 weeks for dose-expansion EC)

07

Results

Posted Feb 17, 2021

Participant flow

A total of 206 participants were enrolled in this study, of whom 69 participants (44 to receive Schedule A and 25 to receive Schedule B treatment) were entered in dose-escalation phase and 137 participants (113 with epithelial ovarian cancer \[EOC\] and 24 with endometrial cancer \[EC\]) were entered in dose-expansion phase. Doses calculated initially based on participant's total body weight (TBW); then from protocol amendment 5 onwards, calculated based on adjusted ideal body weight (AIBW).

Dose Escalation: Maximum 101.3 Weeks
Participant flow — Dose Escalation: Maximum 101.3 Weeks
MilestoneDose Escalation: Schedule A (Mirvetuximab Soravtansine 0.15 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.5 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 1.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 2.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 3.3 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 5.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 6.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 7.0 mg/kg Q3W)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.1 mg/kg Weekly)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.8 mg/kg Weekly)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.0 mg/kg Weekly)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.5 mg/kg Weekly)Dose Expansion: Cohort 1 (Mirvetuximab Soravtansine Q3W)Dose Expansion: Cohort 2 (Mirvetuximab Soravtansine Q3W)Dose Expansion: Cohort 3 (Mirvetuximab Soravtansine Q3W)Dose Expansion: Cohort 5 (Mirvetuximab Soravtansine Q3W)
Started21119187554970000
Received at least 1 dose of study drug21119187554970000
Completed0000000000000000
Not completed21119187554970000
Withdrew: Adverse event0000100110110000
Withdrew: Disease progression01118135433630000
Withdrew: Clinical progression0000022001120000
Withdrew: Began new anticancer therapy0000010000010000
Withdrew: Withdrawal by subject0000010000000000
Withdrew: Investigator decision0000000010000000
Withdrew: Death2000010000100000
Dose Expansion: Maximum 124 Weeks
Participant flow — Dose Expansion: Maximum 124 Weeks
MilestoneDose Escalation: Schedule A (Mirvetuximab Soravtansine 0.15 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.5 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 1.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 2.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 3.3 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 5.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 6.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 7.0 mg/kg Q3W)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.1 mg/kg Weekly)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.8 mg/kg Weekly)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.0 mg/kg Weekly)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.5 mg/kg Weekly)Dose Expansion: Cohort 1 (Mirvetuximab Soravtansine Q3W)Dose Expansion: Cohort 2 (Mirvetuximab Soravtansine Q3W)Dose Expansion: Cohort 3 (Mirvetuximab Soravtansine Q3W)Dose Expansion: Cohort 5 (Mirvetuximab Soravtansine Q3W)
Started00000000000046242740
Completed0000000000000000
Not completed00000000000046242740
Withdrew: Adverse event0000000000004222
Withdrew: Disease progression00000000000032132027
Withdrew: Clinical progression0000000000003332
Withdrew: Began new anticancer therapy0000000000001000
Withdrew: Withdrawal by subject0000000000001425
Withdrew: Investigator decision0000000000000001
Withdrew: Death0000000000004203
Withdrew: Other than specified0000000000001000

Outcome measures

PrimaryDose-Escalation Phase: Maximum Tolerated Dose (MTD) of Mirvetuximab Soravtansine

MTD was defined as the highest dose at which 1 or fewer among 6 participants or less than or equal to (\<=) 33 percent (%) experienced a dose-limiting toxicity (DLT) (calculated based on adjusted ideal body weight \[AIBW\]). AIBW was calculated as ideal body weight (IBW) + 0.4 \* (actual weight - IBW), where IBW for men was 0.9 \* height in centimeters (cm) - 88 and IBW for women was 0.9 \* height in cm - 92. DLT was defined as a treatment-emergent adverse event (TEAE) or abnormal laboratory value related to study treatment (that is, assessed as unrelated to disease, intercurrent illness, or concomitant medications), including those TEAEs and abnormal laboratory values that resulted in a failure to meet the criteria for re-treatment.

Time frame:
Cycle 1 (21 days)
Reported as:
Number · mg/kg
Dose-Escalation Phase: Maximum Tolerated Dose (MTD) of Mirvetuximab Soravtansine
mg/kgDose Escalation: Schedule A (Mirvetuximab Soravtansine Q3W)Dose Escalation: Schedule B (Mirvetuximab Soravtansine Weekly)
Dose-Escalation Phase: Maximum Tolerated Dose (MTD) of Mirvetuximab Soravtansine6.02.0
PrimaryDose-Escalation Phase: Recommended Phase 2 Dose (RP2D) of Mirvetuximab Soravtansine

RP2D was determined by MTD. MTD was defined as the highest dose at which 1 or fewer among 6 participants or \<=33% experienced a DLT. DLT was defined as a TEAE or abnormal laboratory value related to study treatment (that is, assessed as unrelated to disease, intercurrent illness, or concomitant medications), including those TEAEs and abnormal laboratory values that resulted in a failure to meet the criteria for re-treatment. Available clinical data indicated that the MTD defined for the Q3W schedule was equal to the RP2D.

Time frame:
Cycle 1 (21 days)
Reported as:
Number · mg/kg
Dose-Escalation Phase: Recommended Phase 2 Dose (RP2D) of Mirvetuximab Soravtansine
mg/kgDose Escalation: Schedule A (Mirvetuximab Soravtansine Q3W)
Dose-Escalation Phase: Recommended Phase 2 Dose (RP2D) of Mirvetuximab Soravtansine6.0
SecondaryNumber of Participants With TEAEs

An adverse event (AE) was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to study drug. Severity was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03 on following scale: Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening, Grade 5=death. Serious AEs include death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized the participant and required medical intervention to prevent 1 of the outcomes listed in this definition. TEAEs were defined as any AE that emerged on or after the first dose, and within 28 days of the last dose.

Time frame:
From first dose of study drug up to 28 days after last dose of study drug (maximum exposure: 36 weeks for dose-escalation Schedule A, 101.3 weeks for dose-escalation Schedule B, 124 weeks for dose-expansion EOC, 33.3 weeks for dose-expansion EC)
Reported as:
Count of participants · Participants
Number of Participants With TEAEs
ParticipantsDose Escalation: Schedule A (Mirvetuximab Soravtansine 0.15 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.5 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 1.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 2.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 3.3 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 5.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 6.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 7.0 mg/kg Q3W)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.1 mg/kg Weekly)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.8 mg/kg Weekly)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.0 mg/kg Weekly)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.5 mg/kg Weekly)Dose Expansion: Cohort 1 (Mirvetuximab Soravtansine Q3W)Dose Expansion: Cohort 2 (Mirvetuximab Soravtansine Q3W)Dose Expansion: Cohort 3 (Mirvetuximab Soravtansine Q3W)Dose Expansion: Cohort 5 (Mirvetuximab Soravtansine Q3W)
Any TEAE210191875549746242740
SAEs2100051223441811917
Grade >=3 TEAEs21011813234424121424
SecondaryNumber of Participants With Shift From Baseline Grade <=2 in Clinical Laboratory Parameters to Grade 3 or Grade 4 on Study

Laboratory parameters included serum chemistry (alanine aminotransferase \[ALT\]/serum glutamic pyruvic transaminase \[SGPT\], aspartate aminotransferase \[AST\]/serum glutamic oxaloacetic transaminase \[SGOT\], albumin, alkaline phosphatase, bilirubin, calcium, creatinine, glucose, magnesium, phosphorous, potassium, sodium), hematology (hemoglobin, lymphocytes, neutrophils, platelets, white blood cells) and coagulation (international normalized ratio \[INR\], partial thromboplastin time \[PTT\]). Clinically significant laboratory values were defined as per NCI CTCAE v.03 Grade 3 or higher. A grading (severity) scale was provided with grades ranging from 0 (none), 1 (mild), 2 (moderate), 3 (severe), 4 (life-threatening or disabling), to 5 (death). Only participants who shifted from a baseline value of Grade \<=2 to a post-baseline Grade 3/4 on-treatment, are reported.

Time frame:
From first dose of study drug up to 28 days after last dose of study drug (maximum exposure: 36 weeks for dose-escalation Schedule A, 101.3 weeks for dose-escalation Schedule B, 124 weeks for dose-expansion EOC, 33.3 weeks for dose-expansion EC)
Reported as:
Count of participants · Participants
Number of Participants With Shift From Baseline Grade <=2 in Clinical Laboratory Parameters to Grade 3 or Grade 4 on Study
ParticipantsDose Escalation: Schedule A (Mirvetuximab Soravtansine 0.15 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.5 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 1.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 2.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 3.3 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 5.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 6.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 7.0 mg/kg Q3W)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.1 mg/kg Weekly)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.8 mg/kg Weekly)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.0 mg/kg Weekly)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.5 mg/kg Weekly)Dose Expansion: Cohort 1 (Mirvetuximab Soravtansine Q3W)Dose Expansion: Cohort 2 (Mirvetuximab Soravtansine Q3W)Dose Expansion: Cohort 3 (Mirvetuximab Soravtansine Q3W)Dose Expansion: Cohort 5 (Mirvetuximab Soravtansine Q3W)
Glucose: Grade 0 to Grade 30000000000001000
Magnesium: Grade 2 to Grade 30000000000001000
PTT: Grade 2 to Grade 30000000010000000
Lymphocytes: Grade 0 to Grade 30000000000000100
Lymphocytes: Grade 2 to Grade 30000000000000101
SecondaryNumber of Participants With Clinically Significant Abnormalities in Physical Examination Findings and Vital Signs

Physical examination included assessments of general appearance, skin, head (eyes, ears, nose, and throat), neck, lungs, heart, abdomen, back, lymph nodes, extremities, and neurological system. Vital signs included assessment of blood pressure, pulse rate, respiratory rate and body temperature.

Time frame:
From first dose of study drug up to 28 days after last dose of study drug (maximum exposure: 36 weeks for dose-escalation Schedule A, 101.3 weeks for dose-escalation Schedule B, 124 weeks for dose-expansion EOC, 33.3 weeks for dose-expansion EC)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Physical Examination Findings and Vital Signs
ParticipantsDose Escalation: Schedule A (Mirvetuximab Soravtansine 0.15 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.5 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 1.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 2.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 3.3 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 5.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 6.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 7.0 mg/kg Q3W)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.1 mg/kg Weekly)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.8 mg/kg Weekly)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.0 mg/kg Weekly)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.5 mg/kg Weekly)Dose Expansion: Cohort 1 (Mirvetuximab Soravtansine Q3W)Dose Expansion: Cohort 2 (Mirvetuximab Soravtansine Q3W)Dose Expansion: Cohort 3 (Mirvetuximab Soravtansine Q3W)Dose Expansion: Cohort 5 (Mirvetuximab Soravtansine Q3W)
Number of Participants With Clinically Significant Abnormalities in Physical Examination Findings and Vital Signs0000000000000000
SecondaryNumber of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG)

Standard ECGs were performed in triplicate at 2- to 5-minute intervals during the study. A single ECG was performed at the end of treatment visit and as clinically indicated.

Time frame:
Baseline up to end of treatment (EOT) (up to maximum 124 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG)
ParticipantsDose Escalation: Schedule A (Mirvetuximab Soravtansine 0.15 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.5 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 1.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 2.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 3.3 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 5.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 6.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 7.0 mg/kg Q3W)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.1 mg/kg Weekly)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.8 mg/kg Weekly)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.0 mg/kg Weekly)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.5 mg/kg Weekly)Dose Expansion: Cohort 1 (Mirvetuximab Soravtansine Q3W)Dose Expansion: Cohort 2 (Mirvetuximab Soravtansine Q3W)Dose Expansion: Cohort 3 (Mirvetuximab Soravtansine Q3W)Dose Expansion: Cohort 5 (Mirvetuximab Soravtansine Q3W)
Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG)0000000000032110
SecondaryNumber of Participants With Treatment-Emergent Ocular AEs

Ocular AEs included keratopathy and blurred vision. An AE was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to study drug. TEAEs were defined as any AE that emerged on or after the first dose, and within 28 days of the last dose.

Time frame:
From first dose of study drug up to 28 days after last dose of study drug (maximum exposure: 36 weeks for dose-escalation Schedule A, 101.3 weeks for dose-escalation Schedule B, 124 weeks for dose-expansion EOC, 33.3 weeks for dose-expansion EC)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Ocular AEs
ParticipantsDose Escalation: Schedule A (Mirvetuximab Soravtansine 0.15 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.5 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 1.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 2.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 3.3 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 5.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 6.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 7.0 mg/kg Q3W)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.1 mg/kg Weekly)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.8 mg/kg Weekly)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.0 mg/kg Weekly)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.5 mg/kg Weekly)Dose Expansion: Cohort 1 (Mirvetuximab Soravtansine Q3W)Dose Expansion: Cohort 2 (Mirvetuximab Soravtansine Q3W)Dose Expansion: Cohort 3 (Mirvetuximab Soravtansine Q3W)Dose Expansion: Cohort 5 (Mirvetuximab Soravtansine Q3W)
Number of Participants With Treatment-Emergent Ocular AEs0000142503022491418
SecondaryMaximum Observed Plasma Concentration (Cmax) of Mirvetuximab Soravtansine and Total M9346A Antibody at RP2D

Pharmacokinetic (PK) parameters were calculated using standard non-compartmental methods. PK analysis of mirvetuximab soravtansine and total M9346A antibody is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.

Time frame:
Cycle 1, 3: Day 1 (pre-infusion; within 10 minutes [min] of EOI; 2, 4, 6, 8 hrs post-infusion); Day 2, 3 (24, 48 hrs post-infusion); Day 4 or 5, 8, 15 (24 hrs post-infusion)
Reported as:
Mean · micrograms per milliliter (mcg/mL)
Maximum Observed Plasma Concentration (Cmax) of Mirvetuximab Soravtansine and Total M9346A Antibody at RP2D
micrograms per milliliter (mcg/mL)Mirvetuximab Soravtansine 6.0 mg/kg AIBW
Mirvetuximab soravtansine at Cycle 1146.9 ± 30.14
Mirvetuximab soravtansine at Cycle 3154.6 ± 33.08
Total M9346A antibody at Cycle 1149.2 ± 33.74
Total M9346A antibody at Cycle 3170.4 ± 40.55
SecondaryCmax of Free DM4 and S-Methyl DM4 at RP2D

PK parameters were calculated using standard non-compartmental methods. PK analysis of free N2'-\[4-\[(3-carboxypropyl)dithio\]-4-methyl-1-oxo-2-sulfopentyl\]-N2'-deacetylmaytansine (DM4) and S-methyl DM4 is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.

Time frame:
Cycle 1, 3: Day 1 (pre-infusion; within 10 min of EOI; 2, 4, 6, 8 hrs post-infusion); Day 2, 3 (24, 48 hrs post-infusion); Day 4 or 5, 8, 15 (24 hrs post-infusion)
Reported as:
Mean · nanograms per milliliter (ng/mL)
Cmax of Free DM4 and S-Methyl DM4 at RP2D
nanograms per milliliter (ng/mL)Mirvetuximab Soravtansine 6.0 mg/kg AIBW
DM4 at Cycle 15.014 ± 3.119
DM4 at Cycle 35.016 ± 2.389
S-methyl DM4 at Cycle 112.43 ± 12.39
S-methyl DM4 at Cycle 39.974 ± 5.485
SecondaryArea Under the Plasma Concentration-Time Curve Extrapolated to Infinity (AUC0-inf) of Mirvetuximab Soravtansine and Total M9346A Antibody at RP2D

PK parameters were calculated using standard non-compartmental methods. PK analysis of mirvetuximab soravtansine and total M9346A antibody is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.

Time frame:
Cycle 1, 3: Day 1 (pre-infusion; within 10 min of EOI; 2, 4, 6, 8 hrs post-infusion); Day 2, 3 (24, 48 hrs post-infusion); Day 4 or 5, 8, 15 (24 hrs post-infusion)
Reported as:
Mean · hours*milligrams/milliliter (hr*mg/mL)
Area Under the Plasma Concentration-Time Curve Extrapolated to Infinity (AUC0-inf) of Mirvetuximab Soravtansine and Total M9346A Antibody at RP2D
hours*milligrams/milliliter (hr*mg/mL)Mirvetuximab Soravtansine 6.0 mg/kg AIBW
Mirvetuximab soravtansine at Cycle 117.39 ± 4.341
Mirvetuximab soravtansine at Cycle 320.40 ± 5.144
Total M9346A antibody at Cycle 124.00 ± 7.316
Total M9346A antibody at Cycle 337.27 ± 12.54
SecondaryAUC0-inf of Free DM4 and S-Methyl DM4 at RP2D

PK parameters were calculated using standard non-compartmental methods. PK analysis of free DM4 and S-methyl DM4 is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.

Time frame:
Cycle 1, 3: Day 1 (pre-infusion; within 10 min of EOI; 2, 4, 6, 8 hrs post-infusion); Day 2, 3 (24, 48 hrs post-infusion); Day 4 or 5, 8, 15 (24 hrs post-infusion)
Reported as:
Mean · hours*nanograms/milliliter (hr*ng/mL)
AUC0-inf of Free DM4 and S-Methyl DM4 at RP2D
hours*nanograms/milliliter (hr*ng/mL)Mirvetuximab Soravtansine 6.0 mg/kg AIBW
DM4 at Cycle 1292.9 ± 129.2
DM4 at Cycle 3290.6 ± 98.52
S-methyl DM4 at Cycle 12656 ± 2722
S-methyl DM4 at Cycle 31928 ± 1108
SecondaryArea Under the Plasma Concentration-Versus Time Curve From Time of Dose Until Tlast (AUClast) of Mirvetuximab Soravtansine and Total M9346A Antibody at RP2D

PK parameters were calculated using standard non-compartmental methods. PK analysis of mirvetuximab soravtansine and total M9346A antibody is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.

Time frame:
Cycle 1, 3: Day 1 (pre-infusion; within 10 min of EOI; 2, 4, 6, 8 hrs post-infusion); Day 2, 3 (24, 48 hrs post-infusion); Day 4 or 5, 8, 15 (24 hrs post-infusion)
Reported as:
Mean · hr*mg/mL
Area Under the Plasma Concentration-Versus Time Curve From Time of Dose Until Tlast (AUClast) of Mirvetuximab Soravtansine and Total M9346A Antibody at RP2D
hr*mg/mLMirvetuximab Soravtansine 6.0 mg/kg AIBW
Mirvetuximab soravtansine at Cycle 116.44 ± 4.177
Mirvetuximab soravtansine at Cycle 318.91 ± 4.940
Total M9346A antibody at Cycle 120.27 ± 5.903
Total M9346A antibody at Cycle 329.29 ± 9.613
SecondaryAUClast of Free DM4 and S-Methyl DM4 at RP2D

PK parameters were calculated using standard non-compartmental methods. PK analysis of free DM4 and S-methyl DM4 is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.

Time frame:
Cycle 1, 3: Day 1 (pre-infusion; within 10 min of EOI; 2, 4, 6, 8 hrs post-infusion); Day 2, 3 (24, 48 hrs post-infusion); Day 4 or 5, 8, 15 (24 hrs post-infusion)
Reported as:
Mean · hr*ng/mL
AUClast of Free DM4 and S-Methyl DM4 at RP2D
hr*ng/mLMirvetuximab Soravtansine 6.0 mg/kg AIBW
DM4 at Cycle 1246.0 ± 133.3
DM4 at Cycle 3270.1 ± 95.62
S-methyl DM4 at Cycle 12485 ± 2536
S-methyl DM4 at Cycle 31806 ± 1046
SecondaryTerminal Half-Life (t1/2) of Mirvetuximab Soravtansine,Total M9346A Antibody, DM4, and S-Methyl DM4 at RP2D

PK parameters were calculated using standard non-compartmental methods. PK analysis of mirvetuximab soravtansine, total M9346A antibody, DM4, and S-methyl DM4 is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.

Time frame:
Cycle 1, 3: Day 1 (pre-infusion; within 10 min of EOI; 2, 4, 6, 8 hrs post-infusion); Day 2, 3 (24, 48 hrs post-infusion); Day 4 or 5, 8, 15 (24 hrs post-infusion)
Reported as:
Mean · hours
Terminal Half-Life (t1/2) of Mirvetuximab Soravtansine,Total M9346A Antibody, DM4, and S-Methyl DM4 at RP2D
hoursMirvetuximab Soravtansine 6.0 mg/kg AIBW
Mirvetuximab soravtansine at Cycle 1119.4 ± 22.58
Mirvetuximab soravtansine at Cycle 3127.8 ± 34.11
Total M9346A antibody at Cycle 1186.7 ± 54.04
Total M9346A antibody at Cycle 3218.8 ± 71.46
DM4 at Cycle 173.80 ± 28.99
DM4 at Cycle 380.62 ± 26.12
S-methyl DM4 at Cycle 1122.2 ± 25.23
S-methyl DM4 at Cycle 3130.4 ± 23.47
SecondaryClearance (CL) of Mirvetuximab Soravtansine and Total M9346A Antibody at RP2D

PK parameters were calculated using standard non-compartmental methods. PK analysis of mirvetuximab soravtansine and total M9346A antibody is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.

Time frame:
Cycle 1, 3: Day 1 (pre-infusion; within 10 min of EOI; 2, 4, 6, 8 hrs post-infusion); Day 2, 3 (24, 48 hrs post-infusion); Day 4 or 5, 8, 15 (24 hrs post-infusion)
Reported as:
Mean · milliliters per hour (mL/hr)
Clearance (CL) of Mirvetuximab Soravtansine and Total M9346A Antibody at RP2D
milliliters per hour (mL/hr)Mirvetuximab Soravtansine 6.0 mg/kg AIBW
Mirvetuximab soravtansine at Cycle 122.20 ± 6.476
Mirvetuximab soravtansine at Cycle 319.80 ± 4.953
Total M9346A antibody at Cycle 116.89 ± 7.155
Total M9346A antibody at Cycle 313.26 ± 4.956
SecondaryCL of DM4 and S-Methyl DM4 at RP2D

PK parameters were calculated using standard non-compartmental methods. PK analysis of DM4 and S-methyl DM4 is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.

Time frame:
Cycle 1, 3: Day 1 (pre-infusion; within 10 min of EOI; 2, 4, 6, 8 hrs post-infusion); Day 2, 3 (24, 48 hrs post-infusion); Day 4 or 5, 8, 15 (24 hrs post-infusion)
Reported as:
Mean · Liters per hour (L/hr)
CL of DM4 and S-Methyl DM4 at RP2D
Liters per hour (L/hr)Mirvetuximab Soravtansine 6.0 mg/kg AIBW
DM4 at Cycle 11421 ± 560.2
DM4 at Cycle 31338 ± 438.8
S-methyl DM4 at Cycle 1218.9 ± 128.5
S-methyl DM4 at Cycle 3258.4 ± 173.8
SecondaryTime to Reach Maximum Observed Concentration (Tmax) of Mirvetuximab Soravtansine, Free DM4, S-Methyl DM4, and Total M9346A Antibody at RP2D

PK parameters were calculated using standard non-compartmental methods. PK analysis of mirvetuximab soravtansine, free DM4, S-methyl DM4, and total M9346A antibody is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.

Time frame:
Cycle 1, 3: Day 1 (pre-infusion; within 10 min of EOI; 2, 4, 6, 8 hrs post-infusion); Day 2, 3 (24, 48 hrs post-infusion); Day 4 or 5, 8, 15 (24 hrs post-infusion)
Reported as:
Median · hours
Time to Reach Maximum Observed Concentration (Tmax) of Mirvetuximab Soravtansine, Free DM4, S-Methyl DM4, and Total M9346A Antibody at RP2D
hoursMirvetuximab Soravtansine 6.0 mg/kg AIBW
Mirvetuximab soravtansine at Cycle 13.80 (1.2 to 24)
Mirvetuximab soravtansine at Cycle 33.20 (1.1 to 47)
Total M9346A antibody at Cycle 13.60 (1.1 to 53)
Total M9346A antibody at Cycle 33.20 (0.93 to 170)
DM4 at Cycle 15.80 (1.7 to 500)
DM4 at Cycle 35.00 (1.1 to 670)
S-methyl DM4 at Cycle 149.0 (5.8 to 500)
S-methyl DM4 at Cycle 323.0 (4.5 to 670)
SecondaryVolume of Distribution at Steady State (Vss) of Mirvetuximab Soravtansine Free DM4, S-Methyl DM4, and Total M9346A Antibody at RP2D

PK parameters were calculated using standard non-compartmental methods. PK analysis of mirvetuximab soravtansine, free DM4, S-methyl DM4, and total M9346A antibody is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.

Time frame:
Cycle 1, 3: Day 1 (pre-infusion; within 10 min of EOI; 2, 4, 6, 8 hrs post-infusion); Day 2, 3 (24, 48 hrs post-infusion); Day 4 or 5, 8, 15 (24 hrs post-infusion)
Reported as:
Mean · Liters
Volume of Distribution at Steady State (Vss) of Mirvetuximab Soravtansine Free DM4, S-Methyl DM4, and Total M9346A Antibody at RP2D
LitersMirvetuximab Soravtansine 6.0 mg/kg AIBW
Mirvetuximab soravtansine at Cycle 13.198 ± 0.7422
Mirvetuximab soravtansine at Cycle 33.172 ± 1.022
Total M9346A antibody at Cycle 13.744 ± 0.9183
Total M9346A antibody at Cycle 33.671 ± 1.185
DM4 at Cycle 1107400 ± 38770
DM4 at Cycle 3114300 ± 48740
S-methyl DM4 at Cycle 141590 ± 27890
S-methyl DM4 at Cycle 347520 ± 40440
SecondaryObjective Response Rate (ORR): Percentage of Participants With Objective Response as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)

ORR was defined as percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR). CR: Disappearance of all target or non-target lesions. All pathological or non-pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeters (mm). PR: At least 30 percent (%) decrease in the sum of the longest diameters (SoD) of target lesions, taking as reference the baseline SoD.

Time frame:
From first dose of study drug until first BOR of CR or PR (maximum exposure: 36 weeks for dose-escalation Schedule A, 101.3 weeks for dose-escalation Schedule B, 124 weeks for dose-expansion EOC, 33.3 weeks for dose-expansion EC)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR): Percentage of Participants With Objective Response as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
percentage of participantsDose Escalation: Schedule A (Mirvetuximab Soravtansine Q3W)Dose Escalation: Schedule B (Mirvetuximab Soravtansine Weekly)Dose Expansion:EOC Participants(Mirvetuximab Soravtansine Q3W)Dose Expansion: EC Participants(Mirvetuximab Soravtansine Q3W)
Objective Response Rate (ORR): Percentage of Participants With Objective Response as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)5 (0.6 to 15.8)13 (2.7 to 32.4)30 (21.8 to 39.4)8 (1.0 to 27.0)
SecondaryDuration of Response (DOR) as Assessed by RECIST v1.1

DOR was defined as the time from the date of the first response (CR or PR), whichever was recorded first, until the date of progressive disease (PD). PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase. DOR was only defined for participants who had a BOR of CR or PR using the method of Kaplan-Meier.

Time frame:
From the date of first response (CR or PR) until the date of PD (maximum exposure: 36 weeks for dose-escalation Schedule A, 101.3 weeks for dose-escalation Schedule B, 124 weeks for dose-expansion EOC, 33.3 weeks for dose-expansion EC)
Reported as:
Median · weeks
Duration of Response (DOR) as Assessed by RECIST v1.1
weeksDose Escalation: Schedule A (Mirvetuximab Soravtansine Q3W)Dose Escalation: Schedule B (Mirvetuximab Soravtansine Weekly)Dose Expansion:EOC Participants(Mirvetuximab Soravtansine Q3W)Dose Expansion: EC Participants(Mirvetuximab Soravtansine Q3W)
Duration of Response (DOR) as Assessed by RECIST v1.121.3 (18.4 to 24.1)60.2 (44.3 to 76.1)19.3 (18.0 to 34.0)28.6 (NA to NA)
SecondaryProgression-Free Survival (PFS) as Assessed by RECIST v1.1

PFS was defined as the time from initiation of study drug until PD or death whichever occurred first, estimated using the Kaplan-Meier method. PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions and appearance of new lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.

Time frame:
From first dose of study drug until PD or death whichever occurred first (maximum exposure: 36 weeks for dose-escalation Schedule A, 101.3 weeks for dose-escalation Schedule B, 124 weeks for dose-expansion EOC, 33.3 weeks for dose-expansion EC)
Reported as:
Median · months
Progression-Free Survival (PFS) as Assessed by RECIST v1.1
monthsDose Escalation: Schedule A (Mirvetuximab Soravtansine Q3W)Dose Escalation: Schedule B (Mirvetuximab Soravtansine Weekly)Dose Expansion:EOC Participants(Mirvetuximab Soravtansine Q3W)Dose Expansion: EC Participants(Mirvetuximab Soravtansine Q3W)
Progression-Free Survival (PFS) as Assessed by RECIST v1.12.6 (1.3 to 3.3)3.9 (1.8 to 11.1)4.3 (3.9 to 5.4)2.8 (1.2 to 4.2)
SecondaryTime to Progression (TTP) as Assessed by RECIST v1.1

TTP was defined as the time from initiation of study drug until PD, estimated using the method of Kaplan-Meier. PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions and appearance of new lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.

Time frame:
From first dose of study drug until PD (maximum exposure: 36 weeks for dose-escalation Schedule A, 101.3 weeks for dose-escalation Schedule B, 124 weeks for dose-expansion EOC, 33.3 weeks for dose-expansion EC)
Reported as:
Median · months
Time to Progression (TTP) as Assessed by RECIST v1.1
monthsDose Escalation: Schedule A (Mirvetuximab Soravtansine Q3W)Dose Escalation: Schedule B (Mirvetuximab Soravtansine Weekly)Dose Expansion:EOC Participants(Mirvetuximab Soravtansine Q3W)Dose Expansion: EC Participants(Mirvetuximab Soravtansine Q3W)
Time to Progression (TTP) as Assessed by RECIST v1.12.7 (1.3 to 3.3)3.9 (1.8 to 11.1)4.4 (4.0 to 5.6)2.8 (1.2 to 6.9)
SecondaryNumber of Participants With Anti-Drug Antibodies (ADA)

During the conduct of the study, a single immunogenicity assay was developed to concurrently detect human antibodies against all components of mirvetuximab soravtansine, including the humanized anti-FOLR1 antibody, the cleavable disulfide linker, and the cytotoxic maytansinoid, DM4. Therefore, immunogenicity results were reported as ADA titers, and did not distinguish between human anti-drug or anti-human titers.

Time frame:
Baseline up to follow-up visit (maximum exposure: 36 weeks for dose-escalation Schedule A, 101.3 weeks for dose-escalation Schedule B, 124 weeks for dose-expansion EOC, 33.3 weeks for dose-expansion EC)
Reported as:
Count of participants · Participants
Number of Participants With Anti-Drug Antibodies (ADA)
ParticipantsDose Escalation: Schedule A (Mirvetuximab Soravtansine 0.15 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.5 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 1.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 2.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 3.3 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 5.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 6.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 7.0 mg/kg Q3W)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.1 mg/kg Weekly)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.8 mg/kg Weekly)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.0 mg/kg Weekly)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.5 mg/kg Weekly)Dose Expansion: Cohort 1 (Mirvetuximab Soravtansine Q3W)Dose Expansion: Cohort 2 (Mirvetuximab Soravtansine Q3W)Dose Expansion: Cohort 3 (Mirvetuximab Soravtansine Q3W)Dose Expansion: Cohort 5 (Mirvetuximab Soravtansine Q3W)
Number of Participants With Anti-Drug Antibodies (ADA)0010110000100722
SecondaryNumber of Participants With Gynecologic Cancer Intergroup (GCIG) CA-125 Criteria Clinical Responses

CA-125 response was defined as at least 50% reduction in CA-125 levels from baseline. The date of response corresponded to the date when the CA 125 level was first reduced by 50%.

Time frame:
From first dose of study drug until CA-125 response (maximum exposure: 36 weeks for dose-escalation Schedule A, 101.3 weeks for dose-escalation Schedule B, 124 weeks for dose-expansion EOC, 33.3 weeks for dose-expansion EC)
Reported as:
Count of participants · Participants
Number of Participants With Gynecologic Cancer Intergroup (GCIG) CA-125 Criteria Clinical Responses
ParticipantsDose Escalation: Schedule A (Mirvetuximab Soravtansine 0.15 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.5 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 1.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 2.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 3.3 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 5.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 6.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 7.0 mg/kg Q3W)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.1 mg/kg Weekly)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.8 mg/kg Weekly)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.0 mg/kg Weekly)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.5 mg/kg Weekly)Dose Expansion: Cohort 1 (Mirvetuximab Soravtansine Q3W)Dose Expansion: Cohort 2 (Mirvetuximab Soravtansine Q3W)Dose Expansion: Cohort 3 (Mirvetuximab Soravtansine Q3W)Dose Expansion: Cohort 5 (Mirvetuximab Soravtansine Q3W)
Number of Participants With Gynecologic Cancer Intergroup (GCIG) CA-125 Criteria Clinical Responses0000031112232341117

Adverse events

Collected over From first dose of study drug up to 28 days after last dose of study drug (maximum exposure: 36 weeks for dose-escalation Schedule A, 101.3 weeks for dose-escalation Schedule B, 124 weeks for dose-expansion EOC, 33.3 weeks for dose-expansion EC). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.15 mg/kg Q3W)2/2 (100%)2/2 (100%)2/2 (100%)
Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.5 mg/kg Q3W)0/1 (0%)0/1 (0%)0/1 (0%)
Dose Escalation: Schedule A (Mirvetuximab Soravtansine 1.0 mg/kg Q3W)0/1 (0%)1/1 (100%)1/1 (100%)
Dose Escalation: Schedule A (Mirvetuximab Soravtansine 2.0 mg/kg Q3W)0/1 (0%)0/1 (0%)1/1 (100%)
Dose Escalation: Schedule A (Mirvetuximab Soravtansine 3.3 mg/kg Q3W)0/9 (0%)0/9 (0%)9/9 (100%)
Dose Escalation: Schedule A (Mirvetuximab Soravtansine 5.0 mg/kg Q3W)1/18 (5.6%)5/18 (27.8%)18/18 (100%)
Dose Escalation: Schedule A (Mirvetuximab Soravtansine 6.0 mg/kg Q3W)0/7 (0%)1/7 (14.3%)7/7 (100%)
Dose Escalation: Schedule A (Mirvetuximab Soravtansine 7.0 mg/kg Q3W)0/5 (0%)2/5 (40%)5/5 (100%)
Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.1 mg/kg Weekly)0/5 (0%)2/5 (40%)5/5 (100%)
Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.8 mg/kg Weekly)0/4 (0%)3/4 (75%)4/4 (100%)
Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.0 mg/kg Weekly)1/9 (11.1%)4/9 (44.4%)9/9 (100%)
Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.5 mg/kg Weekly)0/7 (0%)4/7 (57.1%)7/7 (100%)
Dose Expansion: Cohort 1 (Mirvetuximab Soravtansine Q3W)4/46 (8.7%)18/46 (39.1%)45/46 (97.8%)
Dose Expansion: Cohort 2 (Mirvetuximab Soravtansine Q3W)4/24 (16.7%)11/24 (45.8%)24/24 (100%)
Dose Expansion: Cohort 3 (Mirvetuximab Soravtansine Q3W)1/27 (3.7%)9/27 (33.3%)27/27 (100%)
Dose Expansion: Cohort 5 (Mirvetuximab Soravtansine Q3W)4/40 (10%)17/40 (42.5%)40/40 (100%)
Most frequent serious events
Showing 10 of 68
Most frequent serious events
EventDose Escalation: Schedule A (Mirvetuximab Soravtansine 0.15 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.5 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 1.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 2.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 3.3 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 5.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 6.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 7.0 mg/kg Q3W)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.1 mg/kg Weekly)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.8 mg/kg Weekly)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.0 mg/kg Weekly)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.5 mg/kg Weekly)Dose Expansion: Cohort 1 (Mirvetuximab Soravtansine Q3W)Dose Expansion: Cohort 2 (Mirvetuximab Soravtansine Q3W)Dose Expansion: Cohort 3 (Mirvetuximab Soravtansine Q3W)Dose Expansion: Cohort 5 (Mirvetuximab Soravtansine Q3W)
Small intestinal obstructionGastrointestinal disorders0/20/11/10/10/91/180/70/50/51/41/90/72/460/240/277/40
PneumoniaInfections and infestations1/20/10/10/10/91/180/70/50/50/40/90/71/461/240/271/40
Metastatic neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/20/10/10/10/90/180/70/50/50/40/90/70/460/241/271/40
HypoxiaRespiratory, thoracic and mediastinal disorders0/20/10/10/10/91/180/70/50/51/40/90/71/460/240/270/40
InfluenzaInfections and infestations0/20/10/10/10/90/180/70/50/51/40/90/70/460/240/270/40
HypoglycaemiaMetabolism and nutrition disorders0/20/10/10/10/90/180/70/50/51/40/90/70/460/240/270/40
Punctate keratitisEye disorders0/20/10/10/10/90/180/71/50/50/40/90/70/460/240/270/40
Hip fractureInjury, poisoning and procedural complications0/20/10/10/10/90/180/71/50/50/40/90/70/461/240/270/40
Metastases to central nervous systemNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/20/10/10/10/90/180/70/51/50/40/90/71/461/240/270/40
HaematuriaRenal and urinary disorders0/20/10/10/10/90/180/70/51/50/40/90/70/460/240/270/40
Most frequent other events
Showing 10 of 368
Most frequent other events
EventDose Escalation: Schedule A (Mirvetuximab Soravtansine 0.15 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.5 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 1.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 2.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 3.3 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 5.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 6.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 7.0 mg/kg Q3W)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.1 mg/kg Weekly)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.8 mg/kg Weekly)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.0 mg/kg Weekly)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.5 mg/kg Weekly)Dose Expansion: Cohort 1 (Mirvetuximab Soravtansine Q3W)Dose Expansion: Cohort 2 (Mirvetuximab Soravtansine Q3W)Dose Expansion: Cohort 3 (Mirvetuximab Soravtansine Q3W)Dose Expansion: Cohort 5 (Mirvetuximab Soravtansine Q3W)
ConstipationGastrointestinal disorders0/20/11/10/11/95/181/70/50/51/43/91/74/462/244/277/40
Vision blurredEye disorders0/20/10/10/11/93/182/75/50/53/40/92/723/467/2411/2716/40
HypokalaemiaMetabolism and nutrition disorders0/20/10/11/10/91/181/71/51/50/41/90/710/466/241/278/40
HeadacheNervous system disorders0/20/10/10/12/94/180/72/53/51/45/96/79/466/246/2712/40
Abdominal distensionGastrointestinal disorders0/20/10/10/10/90/180/70/50/53/40/92/73/461/241/278/40
NauseaGastrointestinal disorders0/20/10/10/14/94/181/72/53/52/46/93/719/4610/249/2719/40
ArthralgiaMusculoskeletal and connective tissue disorders0/20/10/10/10/90/180/73/52/50/42/91/73/461/243/273/40
FatigueGeneral disorders1/20/10/10/12/94/184/73/51/51/44/93/719/4612/2412/2723/40
TinnitusEar and labyrinth disorders0/20/10/10/10/90/180/70/53/50/40/90/72/461/240/270/40
DiarrhoeaGastrointestinal disorders1/20/10/10/13/97/182/72/52/51/45/93/724/468/2410/2723/40

Baseline characteristics

Safety population included all participants who were enrolled and received at least 1 dose of study drug.

Age, Categorical
Age, Categorical(Participants)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.15 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.5 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 1.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 2.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 3.3 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 5.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 6.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 7.0 mg/kg Q3W)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.1 mg/kg Weekly)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.8 mg/kg Weekly)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.0 mg/kg Weekly)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.5 mg/kg Weekly)Dose Expansion: Cohort 1 (Mirvetuximab Soravtansine Q3W)Dose Expansion: Cohort 2 (Mirvetuximab Soravtansine Q3W)Dose Expansion: Cohort 3 (Mirvetuximab Soravtansine Q3W)Dose Expansion: Cohort 5 (Mirvetuximab Soravtansine Q3W)Total
<=18 years00000000000000000
Between 18 and 65 years010161143225525101730122
>=65 years2010373232422114101084
Sex: Female, Male
Sex: Female, Male(Participants)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.15 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.5 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 1.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 2.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 3.3 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 5.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 6.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 7.0 mg/kg Q3W)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.1 mg/kg Weekly)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.8 mg/kg Weekly)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.0 mg/kg Weekly)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.5 mg/kg Weekly)Dose Expansion: Cohort 1 (Mirvetuximab Soravtansine Q3W)Dose Expansion: Cohort 2 (Mirvetuximab Soravtansine Q3W)Dose Expansion: Cohort 3 (Mirvetuximab Soravtansine Q3W)Dose Expansion: Cohort 5 (Mirvetuximab Soravtansine Q3W)Total
Female211191654449746242740200
Male00000221100000006
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.15 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.5 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 1.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 2.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 3.3 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 5.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 6.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 7.0 mg/kg Q3W)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.1 mg/kg Weekly)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.8 mg/kg Weekly)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.0 mg/kg Weekly)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.5 mg/kg Weekly)Dose Expansion: Cohort 1 (Mirvetuximab Soravtansine Q3W)Dose Expansion: Cohort 2 (Mirvetuximab Soravtansine Q3W)Dose Expansion: Cohort 3 (Mirvetuximab Soravtansine Q3W)Dose Expansion: Cohort 5 (Mirvetuximab Soravtansine Q3W)Total
Hispanic or Latino00000201100000004
Not Hispanic or Latino211191673449644232633189
Unknown or Not Reported000000010001211713
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.15 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 0.5 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 1.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 2.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 3.3 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 5.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 6.0 mg/kg Q3W)Dose Escalation: Schedule A (Mirvetuximab Soravtansine 7.0 mg/kg Q3W)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.1 mg/kg Weekly)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 1.8 mg/kg Weekly)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.0 mg/kg Weekly)Dose Escalation: Schedule B (Mirvetuximab Soravtansine 2.5 mg/kg Weekly)Dose Expansion: Cohort 1 (Mirvetuximab Soravtansine Q3W)Dose Expansion: Cohort 2 (Mirvetuximab Soravtansine Q3W)Dose Expansion: Cohort 3 (Mirvetuximab Soravtansine Q3W)Dose Expansion: Cohort 5 (Mirvetuximab Soravtansine Q3W)Total
American Indian or Alaska Native00000000000020002
Asian00000010000200238
Native Hawaiian or Other Pacific Islander00000000000000000
Black or African American00002000000020015
White211171865549541232534187
More than one race00000000000000000
Unknown or Not Reported00000000000011024
08

Study locations

12 sites
  • University of Kansas Medical Center Research Institute
    Fairway, Kansas 66205, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02062, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • Barbara Ann Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • University of Oklahoma Stephenson Cancer Center
    Oklahoma City, Oklahoma 73104, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • CTRC at the University of Texas Health Science Center
    San Antonio, Texas 78229, United States
  • Princess Margaret Hospital
    Toronto, Ontario M5G 2M9, Canada
  • McGill University Health Centre
    Montreal, Quebec H4A3J1, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2012 to primary completion in Mar 2018, 68 months.

Results were first posted in Feb 2021, 2 years 10 months after primary completion.

Of 676 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's 68 months is above that.

Counting every sponsor, half of 903 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2012
First posted
Jun 1, 2012
StartActual
Jun 28, 2012
Primary completionActual
Mar 19, 2018
CompletionActual
Mar 19, 2018
Results first posted
Feb 17, 2021
Last update
Feb 17, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01609556
Lead sponsor
ImmunoGen, Inc.
Responsible party
Sponsor
First posted
Jun 1, 2012
Start date
Jun 28, 2012
Primary completion
Mar 19, 2018
Completion
Mar 19, 2018
Results posted
Feb 17, 2021
Last update
Feb 17, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mirvetuximab soravtansine

Start the discussion